CLINICAL EVALUATION OF SINGHYADI KWATHA IN THE MANAGEMENT OF TAMAKA SWASA (BRONCHIAL ASTHMA)
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Effectiveness of Singhyadi Kwatha in the management of Tamaka Shwasa of various etiological factors.
研究概览
简要总结
The disease Tamaka Swasa is predominantly caused by Pranavaha SrotoDushti and in its pathogenesis; Pratiloma Gati of Vata plays an important rolealong with Srotorodha produced by Kapha. Tamaka Swasa is developed by someVata and Kapha Prakopaka Aahara and Vihara. In one of the pathogenesis ofSwasa, Vata is in normal state and Kapha is vitiated with its own etiologicalfactors and this vitiated Kapha in the Uraha Pradesha causes the obstruction inthe normal path of Vata (Prana).
Asthma is one of the most common chronic diseases among childrenworldwide. According to globalasthmareport.org among India’s 1.31 billionpeople, about 6% of children and 2% of adults have asthma as reported in 2018.Asthma affected an estimated 262 million people in 2019 and caused 461 000deaths. By the year 2020, asthma along with COPD will become the third leadingcause of death. Treatment and effective management of asthma saves lives.
In Ayurveda there is effective treatment of asthma and Ayurveda can do a loton this global disease “Bronchial Asthma†described as “Tamaka Swasaâ€. In Ayurvedic literature, numbers of herbal preparations are described forthe management of Tamaka Swasa.
Drugs which are being used as contents of the ‘Singhyadi Kwatha’ are richin properties (Guna) of Kaphaghna, Swasahara, Kaphanissaraka, Kasahara,Shothhara, Hikkanigrahana, Vedanashamaka, Broncho dilatory and antihistaminic effects.
In a view of above study to know the aetiopathogenesis of Tamaka Swasa, To evaluate the efficacy, safety, sustainability & adverse drug reaction ofa trial drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Other
- 盲法
- Open Label
入排标准
- 年龄范围
- 10.00 Year(s) 至 70.00 Year(s)（—）
- 性别
- All
入选标准
- •1.PATIENTS HAVING CHRONICITY BELOW 10 YEARS
- •PATIENTS WHO ARE PRESENTING WITH CLINICAL FEATURES OF TAMAKA SWASA (BRONCHIAL ASTHMA OR ALLERGIC BRONCHIAL ASTHMA) LIKE, BREATHLESSNESS, WHEEZE, PAROXYSM OF ATTACK, COUGH ETC.
- •IRRESPECTIVE OF SEX AND RELIGION.
排除标准
- •a) Age below 10 and above 70 years.
- •b) Patients having asthma due to secondary causes such as drug induced like aspirin.
- •c) Pregnant women and lactating mothers.
- •d) Systemic illness like Tuberculosis, Carcinoma, Endocrine disorders e) Patient having Clinical Features of CCF.
- •f) Patient having the major renal or liver disorders.
结局指标
主要结局
Effectiveness of Singhyadi Kwatha in the management of Tamaka Shwasa of various etiological factors.
时间窗: 45 DAYS for each patients and completion of trial within 6 months from the date of starting of trial (1st October 2022)
次要结局
- To evaluate the safety, sustainability and adverse drug reaction of trial drug.(45 DAYS)